Lonza Group AG (OTCMKTS:LZAGY – Get Free Report) saw a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 200 shares, a drop of 98.9% from the November 15th total of 18,600 shares. Based on an average daily volume of 286,800 shares, the short-interest ratio is currently 0.0 days.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. The Goldman Sachs Group upgraded Lonza Group to a “strong-buy” rating in a research report on Wednesday, October 9th. Redburn Atlantic upgraded shares of Lonza Group to a “strong-buy” rating in a research note on Wednesday, November 27th.
View Our Latest Stock Report on Lonza Group
Lonza Group Stock Up 3.6 %
Lonza Group Company Profile
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.
Read More
- Five stocks we like better than Lonza Group
- What Are the U.K. Market Holidays? How to Invest and Trade
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What does consumer price index measure?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Consumer Discretionary Stocks Ready for a Comeback in 2025
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.